Differential expression of ICOS in patients with TP53 mutations vs the wild-type gene and impact on overall survival. (A) Flow cytometric analysis of ICOS expression on T-cell subsets and NK cells. (B) ICOS^high/PD-1⁻ expression in Tregs of patients based on TP53 mutation status. (C-D) OS in patients based on percentage of ICOS^high/PD-1⁻ Tregs in the total cohort (C) and the TP53 wild-type cohort (D). *P ≤ .05, **P ≤ .01, ***P ≤ .001.